Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2011, vol. 20, nr 2, March-April, p. 131–136

Publication type: original article

Language: English

Synergistic Effect of Normal Human Serum and Antimicrobial Agents Against Colistin-resistant Citrobacter freundii Strains

Synergistyczne działanie normalnej surowicy ludzkiej oraz antybiotyków wobec szczepów Citrobacter freundii opornych na kolistynę

Dorota Tichaczek-Goska1,, Dorota Wojnicz1,

1 Department of Biology and Medical Parasitology, Wroclaw Medical University, Wroclaw, Poland

Abstract

Background. The bactericidal action of normal human serum (NHS) is an important mechanism protecting the host organism against infections caused mainly by Gram-negative bacteria such as strains of the Citrobacter genus. Owing to the complex structure of their outer membrane, many bacterial strains are resistant to complementdependent host defense. Although this phenomenon is rare within Citrobacter spp. strains, serum-resistant bacilli have been found. Antibiotic resistance among bacteria belonging to Enterobacteriaceae is presently a common and serious epidemiological problem.
Objectives. The scope of this study was to investigate the combined effect of NHS and antimicrobial agents against clinical colistin-resistant Citrobacter freundii strains.
Material and Methods. The study was carried out on C. freundii strains isolated from bronchoalveolar lavage. The bactericidal activity of NHS and its combinations with antibiotics at subinhibitory concentrations was determined.
Results. The survival of colistinand serum-resistant C. freundii strains incubated in the suspension of NHS and ½ MICs of colistin was significantly reduced. The combination of NHS with amikacin and colistin sublethal concentrations demonstrated strong bactericidal effects against C. freundii 1553, but not against C. freundii 1338.
Conclusion. The susceptibility to NHS combined with colistin and amikacin at subinhibitory concentrations can vary between bacteria of the same species.

Streszczenie

Wprowadzenie. Bakteriobójcze działanie normalnej surowicy ludzkiej (NSL) jest ważnym czynnikiem chroniącym organizm gospodarza głównie przed zakażeniami wywoływanymi przez bakterie Gram-ujemne, m.in. pałeczki z rodzaju Citrobacter. Wiele bakterii charakteryzuje się opornością na mechanizmy obronne organizmu żywiciela, co jest związane ze złożoną strukturą błony zewnętrznej drobnoustrojów. Oporność na antybiotyki wśród szczepów z rodziny Enterobacteriaceae stanowi poważny problem epidemiologiczny.
Cel pracy. Określenie synergistycznego działania NSL oraz wybranych antybiotyków wobec klinicznych szczepów Citrobacter freundii.
Materiał i metody. Badania przeprowadzono na szczepach C. freundii wyizolowanych z popłuczyn oskrzelowo-pęcherzykowych. Określono bakteriobójcze działanie NSL w połączeniu z podprogowymi stężeniami antybiotyków.
Wyniki. Przeżywalność szczepów bakteryjnych opornych zarówno na NSL, jak i kolistynę została ograniczona pod wpływem NSL oraz ½ MIC kolistyny. Ponadto wykazano zwiększoną podatność szczepu C. freundii 1553 na łączne działanie NSL oraz podprogowych stężeń kolistyny i amikacyny. Zjawiska tego nie odnotowano natomiast w przypadku szczepu C. freundii 1338.
Wnioski. Podatność bakterii na skojarzone działanie NSL i antybiotyków w stężeniach podprogowych może różnić się między szczepami w obrębie tego samego gatunku.

Key words

synergistic effect, colistin, amikacin, human serum

Słowa kluczowe

synergizm, kolistyna, amikacyna, ludzka surowica

References (21)

  1. Joaquin A, Khan S, Russel N, Al Fayez N: Neonatal meningitis and bilateral cerebellar abscesses due to Citrobacter freundii. Pediatr Neurosurg 1991-1992, 17, 23–24.
  2. Badger JL, Stins MF, Kim KS: Citrobacter freundii invades and replicates in human brain microvascular endothelial cells. Infect Immun 1999, 67, 4208–4215.
  3. Williams BJ, Morlin G, Valentine N, Smith AL: Serum resistance in an invasive, nontypeable Haemophilus influenzae strain. Infect Immun 2001, 69, 695–705.
  4. Bugla-Płoskońska G, Futoma-Kołoch B, Rybka J, Gamian A, Doroszkiewicz W: The role of complement activity in the sensitivity of Salmonella O48 strains with sialic acid-containing lipopolysaccharides to the bactericidal action of normal bovine serum. Pol J Vet Sci 2010, 13, 53–62.
  5. Mielnik G, Gamian A, Doroszkiewicz W: Bactericidal activity of normal cord serum (NCS) against Gram-negative rods with sialic acid-containing lipopolysaccharides (LPS). FEMS Immunol Med Microbiol 2001, 31, 169–173.
  6. Chen JH, Siu LK, Fung CP, Lin JC, Yeh KM, Chen TL, Tsai YK, Chang FY: Contribution of outer membrane protein K36 to antimicrobial resistance and virulence in Klebsiella pneumoniae. J Antimicrob Chemother 2010, 65, 986–990.
  7. Franiczek R, Jankowski S: Synergistic effect of cefotaxime and normal human serum on bactericidal activity against urinary strains of Escherichia coli with capsular antigen K1. Acta Microbiol Pol 1993, 42, 243–250.
  8. Cisowska A, Jankowski S, Doroszkiewicz W: Synergistic bactericidal effect of cephalexin and normal cord serum (NCS) against Escherichia coli K1 strains isolated from children with urinary tract infections (UTI). Acta Microbiol Pol 1999, 48, 381–383.
  9. Miglioli PA, Silini R, Carzeri O, Grabocka E, Allerberger F: Antibacterial activity of gentamicin and ciprofloxacin against Gram-negative bacteria: interactions with pig and calf sera. Pharmacol Res 1999, 39, 321–323.
  10. Vakulenko SB, Mobashery S: Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003, 16, 430–450.
  11. Zakariya BP, Bhat V, Harish BN, Arun Babu T, Joseph NM: Neonatal sepsis in a tertiary care hospital in South India: bacteriological profile and antibiotic sensitivity pattern. Indian J Pediatr 2011. [Epub ahead of print]
  12. Falagas ME, Kasiakou SK: Colistin: the revival of polymyxins for the management of multidrug-resistant gramnegative bacterial infections. Clin Infect Dis 2005, 40, 1333–1341.
  13. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama, A, Elmdaghri N, Belabbes H, Benbachir M: Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006, 53, 274–278.
  14. Falagas ME, Grammatikos AP, Michalopoulos A: Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008, 6, 593–600.
  15. National Committee for Clinical Laboratory Standards 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7–A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  16. Cisowska A, Bugla-Płoskońska G, Tichaczek-Goska D, Doroszkiewicz W, Jankowski S: The susceptibility of Escherichia coli strains with sialic acid-containing lipopolysaccharides or capsules to the bactericidal action of normal human serum. 7th conference: Molecular biology in diagnostics of infectious diseases and biotechnology. Warsaw: SGGW, 2004, 41–47 .
  17. Kłak M, Jankowski S: The influence of lipopolysaccharides isolated from Enterobacteriaceae strains on the bactericidal activity of normal cord serum. Adv Clin Exp Med 2010, 1, 57–64.
  18. Wojnicz D, Cisowska A: Composition of the outer membrane proteins of Escherichia coli strains in relation to serum susceptibility after exposure to subinhibitory concentrations of amikacin and ciprofloxacin. Int J Antimicrob Agents 2009, 33, 579–582.
  19. Marques MB, , Brookings ES, Moser SA, Sonke PB, Waites KB: Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997, 41, 881–885.
  20. Tascini C, Urbani L, Biancofiore G, Rossolini GM, Leonildi A, Gemignani G, Bindi ML, Mugnaioli C, Filipponi F, Menichetti F: Colistin in combination with rifampin and imipenem for treating a blaVIM-1 metallobeta-lactamase-producing Enterobacter cloacae disseminated infection in a liver transplant patient. Minerva Anestesiol 2008, 74, 47–49.
  21. Lubasch A, Ziege S, Brodersen B, Borner K, Koeppe P, Lode H: Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. Clin Microbiol Infect 2003, 9, 670–677.
© Wroclaw Medical University